Publication date: Jul 24, 2024
HIV pre-exposure prophylaxis (PrEP) became available in Victoria, Australia, in 2016. We examined non-occupational post-exposure prophylaxis (nPEP) usage among gay, bisexual and other men who have sex with men (MSM) before and after PrEP became available. We included MSM attending Melbourne Sexual Health Centre for nPEP between 2011 and 2021. We analysed three periods: the ‘pre-PrEP’ (01 Jan 2011 to 25 Jul 2016), ‘PrEP before COVID-19’ (26 Jul 2016 to 31 Dec 2019), and ‘PrEP during COVID-19’ (01 Jan 2020 to 31 Dec 2021). There were 222,978 consultations for MSM; 8292 (3. 7%) were nPEP consultations. The proportion of nPEP consultations increased from 3. 3% (3093/94263) in the pre-PrEP period to 4. 3% (3843/89251) in the PrEP before COVID-19 period then dropped to 3. 4% (1356/39464) during the COVID-19 period. Compared to Australian-born MSM, MSM born in Central/South America (adjusted odds ratio [aOR]: 1. 75; 95% confidence interval [CI]: 1. 27-2. 40) had the highest odds of accessing nPEP, followed by Asian-born MSM (aOR: 1. 47; 95% CI: 1. 27-1. 71) after adjusting for PrEP availability and COVID-19. Those newly arrived in Australia in ≤4 years had higher odds (aOR: 1. 14; 95% CI: 1. 05-1. 22) of accessing nPEP than those living in Australia for >4 years. nPEP prescriptions declined with PrEP availability. Newly arrived overseas-born MSM who are unlikely to have access to subsidised PrEP have a higher demand of nPEP. Increasing PrEP education and ensuring equal access is vital in the drive to reduce new HIV diagnoses.
| Concepts | Keywords |
|---|---|
| Hiv | HIV |
| Melbourne | HIV prevention |
| post-exposure prophylaxis | |
| pre-exposure prophylaxis |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Dimethyl sulfone |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Aspartame |